MIGS has no lasting effect on anterior segment parameters

Article

Implantation of the Ex-PRESS miniature device has been found to have no lasting effects on anterior segment parameters, according to recently published data in the Journal of Glaucoma.

Implantation of the Ex-PRESS miniature device has been found to have no lasting effects on anterior segment parameters, according to recently published data in the Journal of Glaucoma.

The study led by Dr Na’ama Hammel (Department of Ophthalmology, Rabin Medical Center, Petah-Tiqva, Israel) analysed 19 eyes of 19 patients to evaluate if the Ex-PRESS miniature glaucoma implant surgery would affect corneal curvature and anterior segment parameters.

The team used the Pentacam rotating Scheimpflug camera (Oculus Inc.) to analyse the eyes preoperatively and then at 1 day, 1 week, 1 month and 3 months postoperatively to determine if there were any changes in parameters. Measurements were taken of the anterior and posterior corneal curvature, anterior and posterior corneal astigmatism, anterior chamber depth (ACD), anterior chamber volume (ACV) and anterior chamber angle before and after surgery.

One day after surgery and at 3 months post-op, the intraocular pressure (IOP) was found to reduce to a statistically significant level. The anterior corneal astigmatism and posterior corneal astigmatism increased, and the ACD and ACV both decreased on the first post-op day. However, at 3 months post-op these changes in anterior segment parameters were not found to be statistically significant.

For more detailed information please view the abstract here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.